Literature DB >> 11510023

Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol.

H P Tan1, J S Markowitz, R A Montgomery, W T Merritt, A S Klein, P J Thuluvath, F F Poordad, W R Maley, B Winters, S B Akinci, S P Gaine.   

Abstract

Portopulmonary hypertension (PPHTN) is no longer an absolute contraindication to orthotopic liver transplantation (OLT). The pre-OLT management of patients with PPHTN requires early diagnosis and chronic therapy with intravenous epoprostenol to decrease pulmonary vascular resistance (PVR). Close follow-up is necessary to reassess pulmonary artery pressures (PAPs) and evaluate right ventricular (RV) function. This assists in the optimal timing of OLT. Successful management also necessitates reassessment of pulmonary artery hemodynamics just before OLT, with clearly defined parameters used to determine whether to proceed. Even with the intraoperative and postoperative availability of potent pulmonary vasodilators, clinical management may be suboptimal in reducing PAP. Adequate reduction in PVR and improvement in RV function in response to chronic epoprostenol therapy may facilitate successful OLT. We present a case report and review the limited experience with this treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11510023     DOI: 10.1053/jlts.2001.26057

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  10 in total

Review 1.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

2.  Portopulmonary hypertension.

Authors:  Sarfraz Saleemi
Journal:  Ann Thorac Med       Date:  2010-01       Impact factor: 2.219

Review 3.  Management of portopulmonary hypertension: new perspectives.

Authors:  Luigi Mancuso; Francesca Scordato; Michela Pieri; Eliana Valerio; Andrea Mancuso
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

4.  Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II).

Authors:  Markus Peck-Radosavljevic; Bernhard Angermayr; Christian Datz; Arnulf Ferlitsch; Monika Ferlitsch; Valentin Fuhrmann; Michael Häfner; Ludwig Kramer; Andreas Maieron; Berit Payer; Thomas Reiberger; Rudolf Stauber; Rudolf Steininger; Michael Trauner; Siegfried Thurnher; Gregor Ulbrich; Wolfgang Vogel; Heinz Zoller; Ivo Graziadei
Journal:  Wien Klin Wochenschr       Date:  2013-04-12       Impact factor: 1.704

Review 5.  Cirrhosis and its complications: evidence based treatment.

Authors:  Salman Nusrat; Muhammad S Khan; Javid Fazili; Mohammad F Madhoun
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

Review 6.  Inhaled treprostinil and pulmonary arterial hypertension.

Authors:  Samuel T Nadler; Jeffrey D Edelman
Journal:  Vasc Health Risk Manag       Date:  2010-12-03

Review 7.  Pulmonary hypertension's variegated landscape: a snapshot.

Authors:  Thomas J Kulik; Eric D Austin
Journal:  Pulm Circ       Date:  2017-03-13       Impact factor: 3.017

8.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Portopulmonary hypertension.

Authors:  Sarfraz Saleemi; Majdy M Idrees
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

9.  Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report.

Authors:  Takashi Onoe; Asuka Tanaka; Kohei Ishiyama; Kentaro Ide; Hirotaka Tashiro; Hideki Ohdan
Journal:  Surg Case Rep       Date:  2018-02-07

10.  Liver transplantation for severe portopulmonary hypertension: A case report and literature review.

Authors:  Xiao-Jie Chen; Zhi-Jun Zhu; Li-Ying Sun; Lin Wei; Zhi-Gui Zeng; Ying Liu; Wei Qu; Liang Zhang
Journal:  World J Clin Cases       Date:  2019-11-06       Impact factor: 1.337

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.